Journal
FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.667763
Keywords
keloid; hypertrophic scar; interleukin; inflammation; therapy
Categories
Funding
- Natural Science Foundation of Liaoning Province [2019-ZD-0929]
Ask authors/readers for more resources
Hypertrophic scar and keloid are fibroproliferative disorders of the skin caused by aberrant wound healing, with inflammation being recognized as the initiator of their formation. Interleukins, known for their role in inflammatory and immune responses, are being explored as potential therapeutic targets for their treatment.
Hypertrophic scar (HS) and keloid are fibroproliferative disorders (FPDs) of the skin due to aberrant wound healing, which cause disfigured appearance, discomfort, dysfunction, psychological stress, and patient frustration. The unclear pathogenesis behind HS and keloid is partially responsible for the clinical treatment stagnancy. However, there are now increasing evidences suggesting that inflammation is the initiator of HS and keloid formation. Interleukins are known to participate in inflammatory and immune responses, and play a critical role in wound healing and scar formation. In this review, we summarize the function of related interleukins, and focus on their potentials as the therapeutic target for the treatment of HS and keloid.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available